Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · IEX Real-Time Price · USD
7.82
+0.22 (2.89%)
Apr 19, 2024, 9:51 AM EDT - Market open
Ironwood Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for IRWD stock have an average target of 19.5, with a low estimate of 14 and a high estimate of 22. The average target predicts an increase of 149.36% from the current stock price of 7.82.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 1, 2024.
Analyst Ratings
The average analyst rating for IRWD stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $20 → $14 | Buy | Maintains | $20 → $14 | +79.03% | Mar 1, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $20 → $21 | Buy | Maintains | $20 → $21 | +168.54% | Feb 16, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $21 | Strong Buy | Initiates | $21 | +168.54% | Jan 17, 2024 |
| Wells Fargo | Wells Fargo | Buy Initiates $20 | Buy | Initiates | $20 | +155.75% | Dec 14, 2023 |
| JMP Securities | JMP Securities | Buy Initiates $22 | Buy | Initiates | $22 | +181.33% | Sep 28, 2023 |
Financial Forecast
Revenue This Year
457.23M
from 442.74M
Increased by 3.27%
Revenue Next Year
497.96M
from 457.23M
Increased by 8.91%
EPS This Year
0.70
from -6.45
EPS Next Year
0.82
from 0.70
Increased by 18.53%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 476.0M | 540.5M | 695.7M | 1.2B | 1.4B |
| Avg | 457.2M | 498.0M | 563.9M | 956.0M | 1.2B |
| Low | 427.8M | 451.9M | 467.5M | 827.8M | 1.1B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 7.5% | 18.2% | 39.7% | 104.6% | 46.0% |
| Avg | 3.3% | 8.9% | 13.2% | 69.5% | 28.8% |
| Low | -3.4% | -1.2% | -6.1% | 46.8% | 11.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.91 | 0.98 | 1.65 | 2.59 | 2.75 |
| Avg | 0.70 | 0.82 | 1.25 | 2.12 | 2.30 |
| Low | 0.50 | 0.65 | 0.84 | 1.55 | 1.84 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 40.4% | 100.5% | 107.4% | 29.7% |
| Avg | - | 18.5% | 51.7% | 69.7% | 8.2% |
| Low | - | -7.0% | 2.3% | 23.8% | -13.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.